Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma

Abstract

Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients with stages 1–2 RCC and having cytogenetic analysis were included. Gain of 5q was observed in 108 patients, more frequently in clear cell (ccRCC) than non-clear cell tumors. Gain of 5q is likely an independent prognostic factor since the concerned patients had a decreased recurrence risk in stages 1–2 RCC, confirmed in multivariable analysis. Detecting 5q gain could enhance recurrence risk assessment, allowing tailored post-surgery surveillance, and reducing unnecessary treatments.

Keywords:

• Renal cell carcinoma
• cytogenetic
• adjuvant treatment
• follow-up
• 5q chromosome

Authors contribution

Conceptualization, data curation: CL, AJP, AD. Formal analysis, funding acquisition: CL. Investigation, Methodology, Project administration, Resources: CL, AP, BS, NR, KC, NK, IF, SL, EW, AB, AD, AJP. Supervision: AJP. Validation, Visualization: CL, AP, BS, KC, AD, AJP. Writing – original draft: CL, AP, AD, AJP. Writing – review & editing: CL, AP, BS, NR, KC, NK, IF, SL, EW, AB, AD, AJP.

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Additional information

Funding

Cedric Lebacle received grant from French association of Urology, Servier foundation, Groupe Pasteur Mutualite, Astellas and Philippe foundation to support this research.